At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 255 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
In Brief
A Phase 2 clinical trial evaluating Bimekizumab for Ankylosing Spondylitis. Completed, enrolled 255 participants across 50 sites in 10 countries.
Detailed Summary
This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesBulgaria, Canada, Czechia, Germany, Hungary, Poland, Russia, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionOct 2022
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartNov 28, 2017
Primary CompletionOct 19, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 8.6 years ago
Interventions
Bimekizumabdrug
Bimekizumab at a prespecified dose.